Agilent to Shift Life Science Focus from R&D to Profits

Agilent's life science R&D spending as a percentage of revenues will shrink from a current level of around 12 percent to the single-digit range as it transitions from development mode to a profit-driving focus.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.